Mizuho Securities analyst Uy Ear maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...

Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...

Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.

We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...

Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...

Listed below are links to the GEN stories reference in this episode of Touching Base Gene Therapy Tested in Mice Offers New ...

Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] ...

A patient died from liver injury while taking the gene therapy Elevidys Sarepta says more than 800 patients have received the ...

The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

Cantor Fitzgerald reiterated their overweight rating on shares of Sarepta Therapeutics (NASDAQ:SRPT – Free Report) in a ...